BAY 41-2272 is a potent sGC stimulator which can increase sGC activity by 400-fold in synergy with NO and based on preclinical evidence (Straub et al., 2001; Dunkern et al., 2007), it could be used for treatment of pulmonary fibrosis. The gene discussed is SGCB; the disease is pulmonary fibrosis.